Syneos Health (NASDAQ:SYNH) updated its FY 2020
Pre-Market earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.33-3.46 for the period, compared to the Thomson Reuters consensus estimate of $3.40. The company issued revenue guidance of $4.37-4.44 billion, compared to the consensus revenue estimate of $4.42 billion.Syneos Health also updated its FY 2021
Pre-Market guidance to 4.09-4.38 EPS.
SYNH stock opened at $75.05 on Thursday. The firm has a market cap of $7.80 billion, a PE ratio of 42.16 and a beta of 1.74. Syneos Health has a 12 month low of $30.02 and a 12 month high of $75.63. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.12 and a quick ratio of 1.12. The firm has a 50 day simple moving average of $67.75 and a 200 day simple moving average of $61.53.
Syneos Health (NASDAQ:SYNH) last released its quarterly earnings data on Thursday, October 29th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.25. The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.12 billion. Syneos Health had a return on equity of 9.63% and a net margin of 4.10%. The company’s revenue was down 6.6% compared to the same quarter last year. During the same period last year, the company posted $0.87 EPS. As a group, sell-side analysts expect that Syneos Health will post 2.76 earnings per share for the current year.
In related news, CEO Alistair Macdonald sold 1,200 shares of Syneos Health stock in a transaction on Tuesday, December 22nd. The shares were sold at an average price of $70.02, for a total value of $84,024.00. Following the completion of the sale, the chief executive officer now owns 245,487 shares of the company’s stock, valued at approximately $17,188,999.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Jason M. Meggs sold 5,552 shares of the company’s stock in a transaction on Wednesday, January 6th. The stock was sold at an average price of $72.00, for a total transaction of $399,744.00. Following the completion of the sale, the chief financial officer now owns 64,503 shares of the company’s stock, valued at $4,644,216. The disclosure for this sale can be found here. Insiders sold 3,242,420 shares of company stock valued at $198,800,919 over the last quarter. Corporate insiders own 0.44% of the company’s stock.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Further Reading: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.